Cancer - New-wiki

Novel	Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
Novel Novel	Symbols NRAS and WDR76	Name 1 NRAS proto-oncogene, GTPase	Name2 WD repeat domain 76	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Adrenal carcinoma Acute myeloid leukemia (AML) Oral cancer Multiple myeloma Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS	Diseases 2
Novel Novel	Symbols NRAS and FBP2	Name 1 NRAS proto-oncogene, GTPase	Name2 fructose-bisphosphatase 2	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 Gluconeogenesis	Drugs 1	Drugs 2	Diseases 1 Adrenal carcinoma Acute myeloid leukemia (AML) Oral cancer Multiple myeloma Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS	Diseases 2
Novel Novel	Symbols MET and TNS3	Name 1 MET proto-oncogene, receptor tyrosine kinase	Name2 tensin 3	Pathway 1 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D mediated inhibition of cell attachment and migration RAF/MAP kinase cascade MET Receptor Activation Negative regulation of MET activity PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates RAS signaling MET activates PI3K/AKT signaling MET activates PTPN11 MET activates PTK2 signaling InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell MET interacts with TNS proteins MET activates RAP1 and RAC1 MET receptor recycling MET activates STAT3 MECP2 regulates neuronal receptors and channels Drug-mediated inhibition of MET activation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 MET interacts with TNS proteins	Drugs 1 Sunitinib K-252a SGX-523 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol AMG-208 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE Crizotinib Cabozantinib Capmatinib Tivozanib Fostamatinib Tivantinib Brigatinib Amuvatinib Tepotinib Amivantamab	Drugs 2	Diseases 1 Cholangiocarcinoma Gastric cancer Renal cell carcinoma	Diseases 2
Novel Novel	Symbols EZH2 and CDKN2B-AS1	Name 1 enhancer of zeste 2 polycomb repressive complex 2 subunit	Name2 CDKN2B and CDKN2A antisense cis and trans regulatory RNA 1	Pathway 1 PRC2 methylates histones and DNA Oxidative Stress Induced Senescence PKMTs methylate histone lysines Activation of anterior HOX genes in hindbrain development during early embryogenesis Regulation of PTEN gene transcription Regulation of PTEN gene transcription Transcriptional Regulation by E2F6 HCMV Early Events Defective pyroptosis Negative Regulation of CDH1 Gene Transcription Regulation of PD-L1(CD274) transcription	Pathway 2	Drugs 1 Tazemetostat CPI-1205	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols EZH2 and DELEC1	Name 1 enhancer of zeste 2 polycomb repressive complex 2 subunit	Name2 deleted in esophageal cancer 1	Pathway 1 PRC2 methylates histones and DNA Oxidative Stress Induced Senescence PKMTs methylate histone lysines Activation of anterior HOX genes in hindbrain development during early embryogenesis Regulation of PTEN gene transcription Regulation of PTEN gene transcription Transcriptional Regulation by E2F6 HCMV Early Events Defective pyroptosis Negative Regulation of CDH1 Gene Transcription Regulation of PD-L1(CD274) transcription	Pathway 2	Drugs 1 Tazemetostat CPI-1205	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols EZH2 and RIN3	Name 1 enhancer of zeste 2 polycomb repressive complex 2 subunit	Name2 Ras and Rab interactor 3	Pathway 1 PRC2 methylates histones and DNA Oxidative Stress Induced Senescence PKMTs methylate histone lysines Activation of anterior HOX genes in hindbrain development during early embryogenesis Regulation of PTEN gene transcription Regulation of PTEN gene transcription Transcriptional Regulation by E2F6 HCMV Early Events Defective pyroptosis Negative Regulation of CDH1 Gene Transcription Regulation of PD-L1(CD274) transcription	Pathway 2 RAB GEFs exchange GTP for GDP on RABs	Drugs 1 Tazemetostat CPI-1205	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols EZH2 and UCA1	Name 1 enhancer of zeste 2 polycomb repressive complex 2 subunit	Name2 urothelial cancer associated 1	Pathway 1 PRC2 methylates histones and DNA Oxidative Stress Induced Senescence PKMTs methylate histone lysines Activation of anterior HOX genes in hindbrain development during early embryogenesis Regulation of PTEN gene transcription Regulation of PTEN gene transcription Transcriptional Regulation by E2F6 HCMV Early Events Defective pyroptosis Negative Regulation of CDH1 Gene Transcription Regulation of PD-L1(CD274) transcription	Pathway 2	Drugs 1 Tazemetostat CPI-1205	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols FLT1 and VEGFB	Name 1 fms related receptor tyrosine kinase 1	Name2 vascular endothelial growth factor B	Pathway 1 Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization	Pathway 2 Platelet degranulation VEGF ligand-receptor interactions VEGF binds to VEGFR leading to receptor dimerization	Drugs 1 Sorafenib Sunitinib Vatalanib TG-100801 OSI-930 Denibulin Linifanib IMC-1C11 Pazopanib Axitinib N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide Regorafenib Lenvatinib Nintedanib Polaprezinc Foreskin fibroblast (neonatal) Tivozanib Fostamatinib Selpercatinib	Drugs 2 Aflibercept	Diseases 1	Diseases 2 Gastric cancer
Novel Novel	Symbols OPRD1 and SLC12A7	Name 1 opioid receptor delta 1	Name2 solute carrier family 12 member 7	Pathway 1 Peptide ligand-binding receptors G alpha (i) signalling events Interleukin-4 and Interleukin-13 signaling	Pathway 2 Cation-coupled Chloride cotransporters	Drugs 1 Tramadol Morphine Codeine Amitriptyline Hydromorphone Methadone Oxycodone Dextromethorphan Butorphanol Dextropropoxyphene Naltrexone Sufentanil Fentanyl Loperamide Nalbuphine Levorphanol Remifentanil Buprenorphine Hydrocodone Diphenoxylate Naloxone Oxymorphone Ketamine Aripiprazole 3-Methylthiofentanyl Dimethylthiambutene Diamorphine Etorphine Carfentanil Diprenorphine Dihydromorphine 3-Methylfentanyl ADL5859 Tapentadol Nalmefene Alvimopan Amisulpride Morphine glucuronide Ketobemidone Cannabidiol Butyrfentanyl Pholcodine Eluxadoline Opium Naldemedine Samidorphan Metenkefalin Medical Cannabis Nabiximols Loxicodegol	Drugs 2 Potassium chloride	Diseases 1	Diseases 2
Novel Novel	Symbols OPRD1 and TMEM237	Name 1 opioid receptor delta 1	Name2 transmembrane protein 237	Pathway 1 Peptide ligand-binding receptors G alpha (i) signalling events Interleukin-4 and Interleukin-13 signaling	Pathway 2	Drugs 1 Tramadol Morphine Codeine Amitriptyline Hydromorphone Methadone Oxycodone Dextromethorphan Butorphanol Dextropropoxyphene Naltrexone Sufentanil Fentanyl Loperamide Nalbuphine Levorphanol Remifentanil Buprenorphine Hydrocodone Diphenoxylate Naloxone Oxymorphone Ketamine Aripiprazole 3-Methylthiofentanyl Dimethylthiambutene Diamorphine Etorphine Carfentanil Diprenorphine Dihydromorphine 3-Methylfentanyl ADL5859 Tapentadol Nalmefene Alvimopan Amisulpride Morphine glucuronide Ketobemidone Cannabidiol Butyrfentanyl Pholcodine Eluxadoline Opium Naldemedine Samidorphan Metenkefalin Medical Cannabis Nabiximols Loxicodegol	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols RHOB and PKN1	Name 1 ras homolog family member B	Name2 protein kinase N1	Pathway 1 GPVI-mediated activation cascade G alpha (12/13) signalling events Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHOB GTPase cycle	Pathway 2 RHO GTPases activate PKNs Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle RAC1 GTPase cycle	Drugs 1 Botulinum toxin type A	Drugs 2 Fostamatinib	Diseases 1	Diseases 2
Novel Novel	Symbols RHOA and PLEKHG6	Name 1 ras homolog family member A	Name2 pleckstrin homology and RhoGEF domain containing G6	Pathway 1 GPVI-mediated activation cascade Axonal growth inhibition (RHOA activation) PI3K/AKT activation Axonal growth stimulation TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G beta:gamma signalling through PI3Kgamma EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse PCP/CE pathway G alpha (12/13) signalling events Sema4D mediated inhibition of cell attachment and migration Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse VEGFA-VEGFR2 Pathway RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins Ovarian tumor domain proteases ERBB2 Regulates Cell Motility Neutrophil degranulation PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases RHOA GTPase cycle SLIT2:ROBO1 increases RHOA activity RHOC GTPase cycle	Pathway 2 RHOA GTPase cycle RAC1 GTPase cycle	Drugs 1 Guanosine-5'-Diphosphate	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols RHOA and PREX1	Name 1 ras homolog family member A	Name2 phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1	Pathway 1 GPVI-mediated activation cascade Axonal growth inhibition (RHOA activation) PI3K/AKT activation Axonal growth stimulation TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G beta:gamma signalling through PI3Kgamma EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse PCP/CE pathway G alpha (12/13) signalling events Sema4D mediated inhibition of cell attachment and migration Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse VEGFA-VEGFR2 Pathway RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins Ovarian tumor domain proteases ERBB2 Regulates Cell Motility Neutrophil degranulation PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases RHOA GTPase cycle SLIT2:ROBO1 increases RHOA activity RHOC GTPase cycle	Pathway 2 NRAGE signals death through JNK G alpha (12/13) signalling events RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOQ GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RAC3 GTPase cycle	Drugs 1 Guanosine-5'-Diphosphate	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols RHOA and ARHGAP23	Name 1 ras homolog family member A	Name2 Rho GTPase activating protein 23	Pathway 1 GPVI-mediated activation cascade Axonal growth inhibition (RHOA activation) PI3K/AKT activation Axonal growth stimulation TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G beta:gamma signalling through PI3Kgamma EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse PCP/CE pathway G alpha (12/13) signalling events Sema4D mediated inhibition of cell attachment and migration Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse VEGFA-VEGFR2 Pathway RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins Ovarian tumor domain proteases ERBB2 Regulates Cell Motility Neutrophil degranulation PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases RHOA GTPase cycle SLIT2:ROBO1 increases RHOA activity RHOC GTPase cycle	Pathway 2 RHOA GTPase cycle RAC1 GTPase cycle	Drugs 1 Guanosine-5'-Diphosphate	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols RHOA and CNTNAP1	Name 1 ras homolog family member A	Name2 contactin associated protein 1	Pathway 1 GPVI-mediated activation cascade Axonal growth inhibition (RHOA activation) PI3K/AKT activation Axonal growth stimulation TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G beta:gamma signalling through PI3Kgamma EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse PCP/CE pathway G alpha (12/13) signalling events Sema4D mediated inhibition of cell attachment and migration Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse VEGFA-VEGFR2 Pathway RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins Ovarian tumor domain proteases ERBB2 Regulates Cell Motility Neutrophil degranulation PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases RHOA GTPase cycle SLIT2:ROBO1 increases RHOA activity RHOC GTPase cycle	Pathway 2 Neurofascin interactions	Drugs 1 Guanosine-5'-Diphosphate	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols PAX9 and WWOX	Name 1 paired box 9	Name2 WW domain containing oxidoreductase	Pathway 1	Pathway 2 Nuclear signaling by ERBB4 Negative regulation of activity of TFAP2 (AP-2) family transcription factors Activation of the TFAP2 (AP-2) family of transcription factors	Drugs 1	Drugs 2	Diseases 1 Tooth agenesis; Hypodontia	Diseases 2
Novel Novel	Symbols PPARA and TNP1	Name 1 peroxisome proliferator activated receptor alpha	Name2 transition protein 1	Pathway 1 BMAL1:CLOCK,NPAS2 activates circadian expression PPARA activates gene expression PPARA activates gene expression Transcriptional activation of mitochondrial biogenesis Activation of gene expression by SREBF (SREBP) Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway Regulation of lipid metabolism by PPARalpha SUMOylation of intracellular receptors Cytoprotection by HMOX1 Heme signaling Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 Expression of BMAL (ARNTL), CLOCK, and NPAS2 RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression	Pathway 2	Drugs 1 alpha-Linolenic acid Icosapent Troglitazone Valproic acid Indomethacin Rosiglitazone Fenoprofen Clofibrate Fenofibrate Ibuprofen Amiodarone Gemfibrozil Bezafibrate Prasterone N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide Flufenamic acid Resveratrol Phthalic Acid Lauric acid Stearic acid Doconexent Palmitic Acid Oleic Acid Caprylic acid Arachidonic Acid Reglitazar Elafibranor Cardarine Muraglitazar Ertiprotafib Ragaglitazar Tesaglitazar GW-590735 Indeglitazar Myristic acid Aleglitazar Clinofibrate Ciprofibrate Dexibuprofen Soybean oil Omega-3 fatty acids Myrrh Isoflavone Leukotriene B4 Fenofibric acid Fish oil	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols PPARA and ZSCAN23	Name 1 peroxisome proliferator activated receptor alpha	Name2 zinc finger and SCAN domain containing 23	Pathway 1 BMAL1:CLOCK,NPAS2 activates circadian expression PPARA activates gene expression PPARA activates gene expression Transcriptional activation of mitochondrial biogenesis Activation of gene expression by SREBF (SREBP) Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway Regulation of lipid metabolism by PPARalpha SUMOylation of intracellular receptors Cytoprotection by HMOX1 Heme signaling Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 Expression of BMAL (ARNTL), CLOCK, and NPAS2 RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression	Pathway 2	Drugs 1 alpha-Linolenic acid Icosapent Troglitazone Valproic acid Indomethacin Rosiglitazone Fenoprofen Clofibrate Fenofibrate Ibuprofen Amiodarone Gemfibrozil Bezafibrate Prasterone N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide Flufenamic acid Resveratrol Phthalic Acid Lauric acid Stearic acid Doconexent Palmitic Acid Oleic Acid Caprylic acid Arachidonic Acid Reglitazar Elafibranor Cardarine Muraglitazar Ertiprotafib Ragaglitazar Tesaglitazar GW-590735 Indeglitazar Myristic acid Aleglitazar Clinofibrate Ciprofibrate Dexibuprofen Soybean oil Omega-3 fatty acids Myrrh Isoflavone Leukotriene B4 Fenofibric acid Fish oil	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols DLG1 and KIF13B	Name 1 discs large MAGUK scaffold protein 1	Name2 kinesin family member 13B	Pathway 1 Trafficking of AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor NrCAM interactions Activation of Ca-permeable Kainate Receptor RAF/MAP kinase cascade Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Pathway 2 COPI-dependent Golgi-to-ER retrograde traffic Kinesins	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel Novel	Symbols DLG1 and GUCY1A2	Name 1 discs large MAGUK scaffold protein 1	Name2 guanylate cyclase 1 soluble subunit alpha 2	Pathway 1 Trafficking of AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor NrCAM interactions Activation of Ca-permeable Kainate Receptor RAF/MAP kinase cascade Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Pathway 2 Nitric oxide stimulates guanylate cyclase Smooth Muscle Contraction Smooth Muscle Contraction	Drugs 1	Drugs 2 Nitric Oxide Isosorbide mononitrate Riociguat Methylene blue Molsidomine Isosorbide Plecanatide	Diseases 1	Diseases 2
Novel	Symbols NRAS and WDR76	Name 1 NRAS proto-oncogene, GTPase	Name2 WD repeat domain 76	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2	Drugs 1	Drugs 2	Diseases 1 Adrenal carcinoma Acute myeloid leukemia (AML) Oral cancer Multiple myeloma Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS	Diseases 2
Novel	Symbols NRAS and FBP2	Name 1 NRAS proto-oncogene, GTPase	Name2 fructose-bisphosphatase 2	Pathway 1 SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4 Signaling by FGFR2 in disease Signaling by FGFR4 in disease Signaling by FGFR1 in disease Signaling by FGFR3 in disease Regulation of RAS by GAPs RAF activation RAF/MAP kinase cascade MAP2K and MAPK activation Negative regulation of MAPK pathway Neutrophil degranulation Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions RAS signaling downstream of NF1 loss-of-function variants Paradoxical activation of RAF signaling by kinase inactive BRAF Insulin receptor signalling cascade PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAS signaling Activated NTRK2 signals through RAS Erythropoietin activates RAS Activated NTRK2 signals through FRS2 and FRS3 Activated NTRK3 signals through RAS FLT3 Signaling Constitutive Signaling by Overexpressed ERBB2 Estrogen-stimulated signaling through PRKCZ RAS processing Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by ERBB2 KD Mutants Signaling by ERBB2 ECD mutants Signaling by ERBB2 TMD/JMD mutants Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants Signaling by PDGFRA extracellular domain mutants Signaling by FLT3 fusion proteins Signaling by FLT3 ITD and TKD mutants Signaling by RAS GAP mutants Signaling by RAS GTPase mutants	Pathway 2 Gluconeogenesis	Drugs 1	Drugs 2	Diseases 1 Adrenal carcinoma Acute myeloid leukemia (AML) Oral cancer Multiple myeloma Malignant melanoma Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Hepatocellular carcinoma Thyroid cancer Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS	Diseases 2
Novel	Symbols MET and TNS3	Name 1 MET proto-oncogene, receptor tyrosine kinase	Name2 tensin 3	Pathway 1 PIP3 activates AKT signaling Constitutive Signaling by Aberrant PI3K in Cancer Sema4D mediated inhibition of cell attachment and migration RAF/MAP kinase cascade MET Receptor Activation Negative regulation of MET activity PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling MET activates RAS signaling MET activates PI3K/AKT signaling MET activates PTPN11 MET activates PTK2 signaling InlB-mediated entry of Listeria monocytogenes into host cell InlB-mediated entry of Listeria monocytogenes into host cell MET interacts with TNS proteins MET activates RAP1 and RAC1 MET receptor recycling MET activates STAT3 MECP2 regulates neuronal receptors and channels Drug-mediated inhibition of MET activation Regulation of MITF-M-dependent genes involved in cell cycle and proliferation	Pathway 2 MET interacts with TNS proteins	Drugs 1 Sunitinib K-252a SGX-523 1-(4-fluorophenyl)-N-[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]-2-oxo-1,2-dihydropyridine-3-carboxamide N-({4-[(2-aminopyridin-4-yl)oxy]-3-fluorophenyl}carbamoyl)-2-(4-fluorophenyl)acetamide 2-(4-fluorophenyl)-N-{[3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]carbamoyl}acetamide N-(3-chlorophenyl)-N-methyl-2-oxo-3-[(3,4,5-trimethyl-1H-pyrrol-2-yl)methyl]-2H-indole-5-sulfonamide 3-[3-(4-methylpiperazin-1-yl)-7-(trifluoromethyl)quinoxalin-5-yl]phenol AMG-208 1-[(2-NITROPHENYL)SULFONYL]-1H-PYRROLO[3,2-B]PYRIDINE-6-CARBOXAMIDE Crizotinib Cabozantinib Capmatinib Tivozanib Fostamatinib Tivantinib Brigatinib Amuvatinib Tepotinib Amivantamab	Drugs 2	Diseases 1 Cholangiocarcinoma Gastric cancer Renal cell carcinoma	Diseases 2
Novel	Symbols EZH2 and CDKN2B-AS1	Name 1 enhancer of zeste 2 polycomb repressive complex 2 subunit	Name2 CDKN2B and CDKN2A antisense cis and trans regulatory RNA 1	Pathway 1 PRC2 methylates histones and DNA Oxidative Stress Induced Senescence PKMTs methylate histone lysines Activation of anterior HOX genes in hindbrain development during early embryogenesis Regulation of PTEN gene transcription Regulation of PTEN gene transcription Transcriptional Regulation by E2F6 HCMV Early Events Defective pyroptosis Negative Regulation of CDH1 Gene Transcription Regulation of PD-L1(CD274) transcription	Pathway 2	Drugs 1 Tazemetostat CPI-1205	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols EZH2 and DELEC1	Name 1 enhancer of zeste 2 polycomb repressive complex 2 subunit	Name2 deleted in esophageal cancer 1	Pathway 1 PRC2 methylates histones and DNA Oxidative Stress Induced Senescence PKMTs methylate histone lysines Activation of anterior HOX genes in hindbrain development during early embryogenesis Regulation of PTEN gene transcription Regulation of PTEN gene transcription Transcriptional Regulation by E2F6 HCMV Early Events Defective pyroptosis Negative Regulation of CDH1 Gene Transcription Regulation of PD-L1(CD274) transcription	Pathway 2	Drugs 1 Tazemetostat CPI-1205	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols EZH2 and RIN3	Name 1 enhancer of zeste 2 polycomb repressive complex 2 subunit	Name2 Ras and Rab interactor 3	Pathway 1 PRC2 methylates histones and DNA Oxidative Stress Induced Senescence PKMTs methylate histone lysines Activation of anterior HOX genes in hindbrain development during early embryogenesis Regulation of PTEN gene transcription Regulation of PTEN gene transcription Transcriptional Regulation by E2F6 HCMV Early Events Defective pyroptosis Negative Regulation of CDH1 Gene Transcription Regulation of PD-L1(CD274) transcription	Pathway 2 RAB GEFs exchange GTP for GDP on RABs	Drugs 1 Tazemetostat CPI-1205	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols EZH2 and UCA1	Name 1 enhancer of zeste 2 polycomb repressive complex 2 subunit	Name2 urothelial cancer associated 1	Pathway 1 PRC2 methylates histones and DNA Oxidative Stress Induced Senescence PKMTs methylate histone lysines Activation of anterior HOX genes in hindbrain development during early embryogenesis Regulation of PTEN gene transcription Regulation of PTEN gene transcription Transcriptional Regulation by E2F6 HCMV Early Events Defective pyroptosis Negative Regulation of CDH1 Gene Transcription Regulation of PD-L1(CD274) transcription	Pathway 2	Drugs 1 Tazemetostat CPI-1205	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols FLT1 and VEGFB	Name 1 fms related receptor tyrosine kinase 1	Name2 vascular endothelial growth factor B	Pathway 1 Neurophilin interactions with VEGF and VEGFR VEGF binds to VEGFR leading to receptor dimerization	Pathway 2 Platelet degranulation VEGF ligand-receptor interactions VEGF binds to VEGFR leading to receptor dimerization	Drugs 1 Sorafenib Sunitinib Vatalanib TG-100801 OSI-930 Denibulin Linifanib IMC-1C11 Pazopanib Axitinib N-(4-chlorophenyl)-2-[(pyridin-4-ylmethyl)amino]benzamide Regorafenib Lenvatinib Nintedanib Polaprezinc Foreskin fibroblast (neonatal) Tivozanib Fostamatinib Selpercatinib	Drugs 2 Aflibercept	Diseases 1	Diseases 2 Gastric cancer
Novel	Symbols OPRD1 and SLC12A7	Name 1 opioid receptor delta 1	Name2 solute carrier family 12 member 7	Pathway 1 Peptide ligand-binding receptors G alpha (i) signalling events Interleukin-4 and Interleukin-13 signaling	Pathway 2 Cation-coupled Chloride cotransporters	Drugs 1 Tramadol Morphine Codeine Amitriptyline Hydromorphone Methadone Oxycodone Dextromethorphan Butorphanol Dextropropoxyphene Naltrexone Sufentanil Fentanyl Loperamide Nalbuphine Levorphanol Remifentanil Buprenorphine Hydrocodone Diphenoxylate Naloxone Oxymorphone Ketamine Aripiprazole 3-Methylthiofentanyl Dimethylthiambutene Diamorphine Etorphine Carfentanil Diprenorphine Dihydromorphine 3-Methylfentanyl ADL5859 Tapentadol Nalmefene Alvimopan Amisulpride Morphine glucuronide Ketobemidone Cannabidiol Butyrfentanyl Pholcodine Eluxadoline Opium Naldemedine Samidorphan Metenkefalin Medical Cannabis Nabiximols Loxicodegol	Drugs 2 Potassium chloride	Diseases 1	Diseases 2
Novel	Symbols OPRD1 and TMEM237	Name 1 opioid receptor delta 1	Name2 transmembrane protein 237	Pathway 1 Peptide ligand-binding receptors G alpha (i) signalling events Interleukin-4 and Interleukin-13 signaling	Pathway 2	Drugs 1 Tramadol Morphine Codeine Amitriptyline Hydromorphone Methadone Oxycodone Dextromethorphan Butorphanol Dextropropoxyphene Naltrexone Sufentanil Fentanyl Loperamide Nalbuphine Levorphanol Remifentanil Buprenorphine Hydrocodone Diphenoxylate Naloxone Oxymorphone Ketamine Aripiprazole 3-Methylthiofentanyl Dimethylthiambutene Diamorphine Etorphine Carfentanil Diprenorphine Dihydromorphine 3-Methylfentanyl ADL5859 Tapentadol Nalmefene Alvimopan Amisulpride Morphine glucuronide Ketobemidone Cannabidiol Butyrfentanyl Pholcodine Eluxadoline Opium Naldemedine Samidorphan Metenkefalin Medical Cannabis Nabiximols Loxicodegol	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols RHOB and PKN1	Name 1 ras homolog family member B	Name2 protein kinase N1	Pathway 1 GPVI-mediated activation cascade G alpha (12/13) signalling events Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHOB GTPase cycle	Pathway 2 RHO GTPases activate PKNs Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle RAC1 GTPase cycle	Drugs 1 Botulinum toxin type A	Drugs 2 Fostamatinib	Diseases 1	Diseases 2
Novel	Symbols RHOA and PLEKHG6	Name 1 ras homolog family member A	Name2 pleckstrin homology and RhoGEF domain containing G6	Pathway 1 GPVI-mediated activation cascade Axonal growth inhibition (RHOA activation) PI3K/AKT activation Axonal growth stimulation TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G beta:gamma signalling through PI3Kgamma EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse PCP/CE pathway G alpha (12/13) signalling events Sema4D mediated inhibition of cell attachment and migration Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse VEGFA-VEGFR2 Pathway RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins Ovarian tumor domain proteases ERBB2 Regulates Cell Motility Neutrophil degranulation PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases RHOA GTPase cycle SLIT2:ROBO1 increases RHOA activity RHOC GTPase cycle	Pathway 2 RHOA GTPase cycle RAC1 GTPase cycle	Drugs 1 Guanosine-5'-Diphosphate	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols RHOA and PREX1	Name 1 ras homolog family member A	Name2 phosphatidylinositol-3,4,5-trisphosphate dependent Rac exchange factor 1	Pathway 1 GPVI-mediated activation cascade Axonal growth inhibition (RHOA activation) PI3K/AKT activation Axonal growth stimulation TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G beta:gamma signalling through PI3Kgamma EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse PCP/CE pathway G alpha (12/13) signalling events Sema4D mediated inhibition of cell attachment and migration Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse VEGFA-VEGFR2 Pathway RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins Ovarian tumor domain proteases ERBB2 Regulates Cell Motility Neutrophil degranulation PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases RHOA GTPase cycle SLIT2:ROBO1 increases RHOA activity RHOC GTPase cycle	Pathway 2 NRAGE signals death through JNK G alpha (12/13) signalling events RHOA GTPase cycle RHOB GTPase cycle RHOC GTPase cycle CDC42 GTPase cycle RAC1 GTPase cycle RAC2 GTPase cycle RHOQ GTPase cycle RHOG GTPase cycle RHOJ GTPase cycle RAC3 GTPase cycle	Drugs 1 Guanosine-5'-Diphosphate	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols RHOA and ARHGAP23	Name 1 ras homolog family member A	Name2 Rho GTPase activating protein 23	Pathway 1 GPVI-mediated activation cascade Axonal growth inhibition (RHOA activation) PI3K/AKT activation Axonal growth stimulation TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G beta:gamma signalling through PI3Kgamma EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse PCP/CE pathway G alpha (12/13) signalling events Sema4D mediated inhibition of cell attachment and migration Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse VEGFA-VEGFR2 Pathway RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins Ovarian tumor domain proteases ERBB2 Regulates Cell Motility Neutrophil degranulation PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases RHOA GTPase cycle SLIT2:ROBO1 increases RHOA activity RHOC GTPase cycle	Pathway 2 RHOA GTPase cycle RAC1 GTPase cycle	Drugs 1 Guanosine-5'-Diphosphate	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols RHOA and CNTNAP1	Name 1 ras homolog family member A	Name2 contactin associated protein 1	Pathway 1 GPVI-mediated activation cascade Axonal growth inhibition (RHOA activation) PI3K/AKT activation Axonal growth stimulation TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G beta:gamma signalling through PI3Kgamma EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse PCP/CE pathway G alpha (12/13) signalling events Sema4D mediated inhibition of cell attachment and migration Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse VEGFA-VEGFR2 Pathway RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins Ovarian tumor domain proteases ERBB2 Regulates Cell Motility Neutrophil degranulation PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases RHOA GTPase cycle SLIT2:ROBO1 increases RHOA activity RHOC GTPase cycle	Pathway 2 Neurofascin interactions	Drugs 1 Guanosine-5'-Diphosphate	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols PAX9 and WWOX	Name 1 paired box 9	Name2 WW domain containing oxidoreductase	Pathway 1	Pathway 2 Nuclear signaling by ERBB4 Negative regulation of activity of TFAP2 (AP-2) family transcription factors Activation of the TFAP2 (AP-2) family of transcription factors	Drugs 1	Drugs 2	Diseases 1 Tooth agenesis; Hypodontia	Diseases 2
Novel	Symbols PPARA and TNP1	Name 1 peroxisome proliferator activated receptor alpha	Name2 transition protein 1	Pathway 1 BMAL1:CLOCK,NPAS2 activates circadian expression PPARA activates gene expression PPARA activates gene expression Transcriptional activation of mitochondrial biogenesis Activation of gene expression by SREBF (SREBP) Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway Regulation of lipid metabolism by PPARalpha SUMOylation of intracellular receptors Cytoprotection by HMOX1 Heme signaling Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 Expression of BMAL (ARNTL), CLOCK, and NPAS2 RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression	Pathway 2	Drugs 1 alpha-Linolenic acid Icosapent Troglitazone Valproic acid Indomethacin Rosiglitazone Fenoprofen Clofibrate Fenofibrate Ibuprofen Amiodarone Gemfibrozil Bezafibrate Prasterone N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide Flufenamic acid Resveratrol Phthalic Acid Lauric acid Stearic acid Doconexent Palmitic Acid Oleic Acid Caprylic acid Arachidonic Acid Reglitazar Elafibranor Cardarine Muraglitazar Ertiprotafib Ragaglitazar Tesaglitazar GW-590735 Indeglitazar Myristic acid Aleglitazar Clinofibrate Ciprofibrate Dexibuprofen Soybean oil Omega-3 fatty acids Myrrh Isoflavone Leukotriene B4 Fenofibric acid Fish oil	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols PPARA and ZSCAN23	Name 1 peroxisome proliferator activated receptor alpha	Name2 zinc finger and SCAN domain containing 23	Pathway 1 BMAL1:CLOCK,NPAS2 activates circadian expression PPARA activates gene expression PPARA activates gene expression Transcriptional activation of mitochondrial biogenesis Activation of gene expression by SREBF (SREBP) Transcriptional regulation of white adipocyte differentiation Nuclear Receptor transcription pathway Regulation of lipid metabolism by PPARalpha SUMOylation of intracellular receptors Cytoprotection by HMOX1 Heme signaling Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 Expression of BMAL (ARNTL), CLOCK, and NPAS2 RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression	Pathway 2	Drugs 1 alpha-Linolenic acid Icosapent Troglitazone Valproic acid Indomethacin Rosiglitazone Fenoprofen Clofibrate Fenofibrate Ibuprofen Amiodarone Gemfibrozil Bezafibrate Prasterone N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide Flufenamic acid Resveratrol Phthalic Acid Lauric acid Stearic acid Doconexent Palmitic Acid Oleic Acid Caprylic acid Arachidonic Acid Reglitazar Elafibranor Cardarine Muraglitazar Ertiprotafib Ragaglitazar Tesaglitazar GW-590735 Indeglitazar Myristic acid Aleglitazar Clinofibrate Ciprofibrate Dexibuprofen Soybean oil Omega-3 fatty acids Myrrh Isoflavone Leukotriene B4 Fenofibric acid Fish oil	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DLG1 and KIF13B	Name 1 discs large MAGUK scaffold protein 1	Name2 kinesin family member 13B	Pathway 1 Trafficking of AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor NrCAM interactions Activation of Ca-permeable Kainate Receptor RAF/MAP kinase cascade Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Pathway 2 COPI-dependent Golgi-to-ER retrograde traffic Kinesins	Drugs 1	Drugs 2	Diseases 1	Diseases 2
Novel	Symbols DLG1 and GUCY1A2	Name 1 discs large MAGUK scaffold protein 1	Name2 guanylate cyclase 1 soluble subunit alpha 2	Pathway 1 Trafficking of AMPA receptors Unblocking of NMDA receptors, glutamate binding and activation Unblocking of NMDA receptors, glutamate binding and activation Ras activation upon Ca2+ influx through NMDA receptor NrCAM interactions Activation of Ca-permeable Kainate Receptor RAF/MAP kinase cascade Synaptic adhesion-like molecules Assembly and cell surface presentation of NMDA receptors Negative regulation of NMDA receptor-mediated neuronal transmission Long-term potentiation	Pathway 2 Nitric oxide stimulates guanylate cyclase Smooth Muscle Contraction Smooth Muscle Contraction	Drugs 1	Drugs 2 Nitric Oxide Isosorbide mononitrate Riociguat Methylene blue Molsidomine Isosorbide Plecanatide	Diseases 1	Diseases 2

Page 42 out of 98 pages

Search Results : Cancer